Publications

Monographs

  1. Barth S. - Konstruktion eines binären Vektorensystems zur Agrobacterium tumefaciens- vermittelten Transformation von Leguminosen. Diplomarbeit am Institut für Biochemische Genetik der Friedrich-Wilhelms-Universität Bonn (1991)
  2. Barth S. - Fusion und Regeneration von Protoplasten der Sonnenblume (Helianthus annuus L.). Entwicklung von Modellen zur Selektion binärer Heterokaryonten. Dissertation (Dr. rer. nat.) am Institut für Landwirtschaftliche Botanik der Friedrich-Wilhelms-Universität Bonn (1994)
  3. Barth S. - Konstruktion, Expression und präklinische Charakterisierung eines rekombinanten anti-CD25 Immuntoxins für den Einsatz beim Hodgkin-Lymphom. Dissertation (Dr. rer. medic.) an der Medizinischen Klinik I der Universität zu Köln (1997)
  4. Barth S. - Konstruktion, Expression und präklinische Charakterisierung rekombinanter Immuntherapeutika für einen Einsatz bei malignen Erkrankungen. Habilitationsschrift an der Medizinischen Fakultät der Universität zu Köln (2000)

 Manuscripts Submitted/In Preparation

  1. Amoury M., Bauerschlag D., Zeppernick F., Berges N., Di Fiore S., Bleilevens A., Maass N., Bräutigam K., Meinhold-Heerlein I., Fischer R., Barth S.*, Hussain A.F.* – Triple on demand activatable photoimmuno-theranosics detect and eliminate triple negative breast cancer cells. submitted
  2. Amoury M., Kolberg K., Pham A.T., Hristodorov D., Mladenov R., Di Fiore S., Helfrich W., Kiessling F., Fischer R., Pardo A., Thepen T., Nachreiner T., Barth S. - Human granzyme B- based cytolytic fusion protein targeting EpCAM specifically kills triple-negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. In preparation
  3. Amoury M., Mladenov R., Nachreiner T., Pham A.T., Hristodorov D., Di Fiore S., Helfrich W., Pardo A., Fey G., Thepen T., Kiessling F., Kolberg K., Barth S. - A novel approach for targeted elimination of CSPG4-positive triple negative breast cancer using a MAP-tau based fusion protein. Submitted
  4. Bialon M., Grezella C., Schellenberg L., Sieben T., Pham A.T., Fischer R., Barth S., Püttmann C., Stein C. - A monoclonal antibody that discriminates between SNAP- and CLIP-tagged proteins. In preparation
  5. Feller T., Naehring J., Spiegel H., Barth S., Fischer R. - Development of a cystatin C-specific bioassay for integration into an implantable biochip system. PLOS ONE: submitted (2014)
  6. Hristodorov D., Mladenov R., Huhn M., Fischer R., Barth S., Thepen T. – H22(scFv)-MAP, a fully human anti-CD64 cytolytic fusion protein with highly specific cytotoxicity against pro- inflammatory M1 macrophages in cutaneous inflammation. In preparation
  7. Lilienthal N., Lohmann G., Crispatzu G., Vasyutina E., Zittrich S., Mayer P., Herling C.D., Tur M.K., Hallek M., Pfitzer G., Barth S., Herling M. – A novel CD22 scFv immunoligand restores lost activity of death-associated protein kinase (DAPK) in neoplastic B cells and mediates specific cytotoxicity. Submitted
  8. Addai-Mensah O., Seidel M., Amidu N., Maskus D.J., Kapelski S., Franken C., Dabo E.O., Frempong M., Schinkel H., Reimann A., Klockenbring T., Barth S., Fischer R., Fendel R. – Acquired immune responses to three malaria vaccine candidates and their relationship to invasion inhibition in two populations naturally exposed to malaria. submitted
  9. Pickert D., Saunders U., Barth S., Fischer R., Jacobi A.M., Nachreiner T. - Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations and their potential impact on autoimmune disease-specific therapies. Submitted
  10. Soares G.*, Thepen T.*, Khouri R.*, Barth S.*, Silva Santos G., Costa J.M., Farré L., van de Winkel J.G., Barral A., Barral-Netto M., van Weyenbergh J. – Circumventing therapeutic failure by host cell elimination in parasitic disease. In preparation

Original Publications

a)First/Senior Author (*shared)

  1. Choudhary S., Pardo S., Rosinke R., Batra J.K. , Barth S.*, Verma R.S.* - Targeting c-kit receptor in neuroblastomas and colorectal cancers using Stem Cell Factor (SCF) l-based recombinant bacterial toxins. Applied Microbiology and Biotechnology: accepted (2015)
  2. Cremer C., Braun H., Mladenov R., Hein L., Cong X., Jost E., Brümmendorf T.H., Fischer R., Carloni P., Barth S.*, Nachreiner T.* - Novel angiogenin mutants with increased cytotoxicity show enhanced depletion of  proinflammatory macrophages and leukemia cells ex vivo. Cancer Immunol Immunother: accepted (2015)
  3. Hristodorov D., Mladenov R., Schiffer S., Aslanian E., Huhn M., von Felbert V., Fischer R., Barth S.*, Thepen T.* - Targeting CD64 mediates elimination of M1 but not M2 macrophages in chronic cutaneous inflammation. mAbs 7(5): 853-62 (2015), PMID: 26218624, doi: 10.1080/19420862.2015.1066950.
  4. Brehm H., Hristodorov D., Pardo A., Mladenov R., Niesen J., Fischer R., Tur M.K., Barth S. - Targeted killing of rhabdomyosarcoma by a MAP-based human cytolytic fusion proteins. Cancer Lett 365(2): 149-55 (2015), PMID: 25888452, doi: 10.1016/j.canlet.2015.04.004
  5. Cremer C., Vierbuchen T., Hein L., Fischer R., Barth S.*, Nachreiner T.* - Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential. J Immunother 38(3): 85-95 (2015), PMID: 25710248, doi: 10.1097/CJI.0000000000000053.
  6. Fitting J., Blume T., ten Haaf A., Blau W., Gattenlöhner S., Tur M.K., Barth S. - Phage display- based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. mAbs 7(2): 390-402 (2015), PMID: 25760770, doi: 10.1080/19420862.2015.1007818.
  7. Kapelski S., de Almeida M., Fischer R., Barth S.*, Fendel R.* - Antimalarial activity of granzyme B and its targeted delivery ba a granzyme B-scFv fusion protein. Antimicrob Agents Chemother 59(1): 669-672 (2015), PMID: 25313223, doi: 10.1128/AAC.04190-14.
  8. Mladenov R., Hristodorov D., Cremer C., Hein L., Kreutzer F., Stroisch T., Niesen J., Brehm H., Blume T., Brümmendorf T., Jost E., Thepen T., Fischer R., Stockmeyer B., Barth S.*, Stein C. - The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. Int J Cancer 137(11): 2729-38 (2015), doi: 10.1002/ijc.29628.
  9. Niesen J., Stein C., Brehm H., Hehmann-Titt G., Fendel R., Melmer G., Fischer R., Barth S. - Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J Cancer Res Clin Oncol: in press (2015), PMID: 25899161, doi: 10.1007/s00432-015-1975-5.
  10. Bialon M., Schellenberg L., Herzog N., Kraus S., Jörißen H., Fischer R., Stein C., Nähring J., Barth S.*, Püttmann C.* - Cloning murine antibody V-genes with non-degenerate primers and conversion to a recombinant antibody format. Monoclon Antib Immunodiagn Immunother 33(6): 369-377 (2014), PMID: 25545205, doi: 10.1089/mab.2014.0044.
  11. Blohm L., Püttmann C., Holz S., Piechotta G., Albers J., Dammers C., Kleines M., Krüttgen A., Melmer G., Nähring J., Barth S.*, Nebling E.* - Rapid detection of human anti-HCV immunoglobulins on electrical biochips. Antibody Technology Journal 4: 23-32 (2014)
  12. Brehm H., Niesen J., Mladenov R., Stein C., Pardo A., Fey G., Helfrich W., Fischer R., Gattenlöhner S., Tur M.K., Barth S. - A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissue. Cancer Lett 352(2): 228-235 (2014), PMID: 25016058, doi: 10.1016/j.canlet.2014.07.006.
  13. Hristodorov D., Mladenov R., Brehm H., Fischer R., Barth S.*, Thepen T. – Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody - a potential strategy to enhance anti-TNF-alpha therapy. mAbs 6(5): 1283-1289 (2014), PMID: 25517313, doi: 10.4161/mabs.32182.
  14. Hristodorov D., Amoury M., Mladenov R., Niesen J., Arens K., Berges N., Hein L., Di Fiore S., Pham A.-T., Huhn M., Helfrich W., Fischer R., Thepen T., Barth S. - EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein. Molecular Cancer Therapeutics 13(9): 2194-2202 (2014), PMID: 24980949, doi: 10.1158/1535-7163.MCT-13- 0781.
  15. Hristodorov D., Nordlohne J., Mladenov R., Schiffer S., Huhn M., Fischer R., Thepen T., Barth S. – Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo. Brit J Haematol 164(2): 251-257 (2014), PMID: 24164493, doi: 10.1111/bjh.12626.
  16. Niesen J., Brehm H., Stein C., Berges N., Pardo A., Fischer R., ten Haaf A., Gattenlöhner S., Tur M.K., Barth S. - In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomysarcoma cells. J Cancer Res Clin Oncol: accepted (2014), PMID: 25433506, DOI:10.1007/s00432-014-1884-z.
  17. Schiffer S., Rosinke R., Jost E., Hehmann-Titt G., Huhn M., Melmer G., Barth S.*, Thepen T.*Targeted ex vivo reduction of CD64-positive monocytes in CMML and AMML using human granzyme B-based cytolytic fusion proteins. Int J Cancer 135(6): 1497-1508 (2014), PMID: 24523193, doi: 10.1002/ijc.28786.
  18. Hristodorov D., Mladenov R., Pardo A., Pham A.T., Huhn M., Fischer R., Thepen T., Barth S. Microtubule-associated protein (MAP) tau facilitates the targeted killing  of proliferating cancer cells in vitro and in a xenograft mouse tumor model in vivo. Brit J Cancer 109(6): 1570- 1578 (2013), PMID: 23942071, doi: 10.1038/bjc.2013.457.
  19. Hussain A.F., Krüger H.R., Kampmeier F., Weissbach T., Licha K., Kratz F., Haag R., Calderon M., Barth S. – Targeted delivery of dendritic polyglycerol-doxorubicin conjugates by scFv- SNAP fusion protein suppresses EGFR+ cancer cell growth. Biomacromolecules 14(8): 2510- 2520 (2013), PMID: 23782069, doi: 10.1021/bm400410e.
  20. Hussain A.F., Tur M.K., Barth S. – An aptamer-siRNA chimera silences eukaryotic elongation Therapeutics 23(3): 203-212 (2013), PMID: 23544955, doi: 10.1089/nat.2012.0408.
  21. Schiffer S., Hansen H., Hehmann-Titt G., Huhn M., Fischer R., Thepen T., Barth S. - Efficacy of an adapted Granzyme B-based anti-CD30 cytolytic fusion protein against Serpin B9- positive, treatment-resistant Hodgkin lymphoma cells. Blood Cancer Journal 3: e106 (2013), PMID: 23524591, doi: 10.1038/bcj.2013.4.
  22. Schiffer S., Hristodorov D., Mladenov R., Aslanian E., Huhn M., Fischer R., Barth S.*, Thepen T.* – Species-dependent functionality of the human cytolytic fusion proteins Granzyme B- H22(scFv) and H22(scFv)-angiogenin in macrophages. Antibodies 2(1): 9-18 (2013)
  23. Schiffer S., Letzian S., Jost E., Mladenov R., Hristodorov D., Huhn M., Fischer R., Barth S.*, Thepen T.* – Granzyme M as a novel effector molecule for human cytolytic fusion proteins:. CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Cancer Lett 341(2): 178- 185 (2013), PMID: 23973499, doi: 10.1016/j.canlet.2013.08.005.
  24. Puettmann C., Kolberg K., Hagen S., Schmies S., Fischer R., Naehring J. Barth S. – A monoclonal antibody for the detection of SNAP/CLIP-labeled proteins. Immunol Lett 150(1-2): 69-74 (2013)
  25. Siepert E.M., Gartz E., Tur M.K., Delbrück H., Barth S.*, Büchs J.* – Short-chain fluorescent tryptophan tags for online detection of functional recombinant proteins. BMC Biotechnology 12: 65 (2012)
  26. Losasso V., Schiffer S., Barth S.*, Carloni P.* – Design of human Granzyme B variants with improved therapeutic potential. Proteins 80(11): 2514-2522 (2012)
  27. Pardo A., Stöcker M., Kampmeier F., Melmer G., Fischer R., Thepen T., Barth S. – In vivo imaging of immunotoxin treatment using Katushka transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother 61(10): 1617-1626 (2012)
  28. Fitting J., Kilian D., Junghanss C., Willenbrock S., Murua Escobar H., Nolte I., Lange S., Barth S.*, Tur M.K.* - Generation of recombinant antibody fragments that target canine dendritic cells by phage display. Veterinary and Comparative Oncology 9(3): 183-195 (2011)
  29. Hussain A., Kampmeier F., von Felbert V., Merk H.F., Tur M.K.*, Barth S.* – SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug. Chem. 22(12): 2487-2495 (2011)
  30. Tur M.K., Huhn M., Jost E., Thepen T., Brümmendorf H., Barth S. – In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA’ in a human acute myeloid leukemia xenograft tumor model. Int. J. Cancer 129(5): 1277-1282 (2011)
  31. Dembski S., Gellermann C., Probst J., Klockenbring T., Barth S. – Multifunctional nanoparticles for biomedical applications. GIT Laboratory Journal 14(11-12): 9-10 (2010)
  32. Gattenlöhner S., Jörißen H., Huhn M., Vincent A.C., Beeson D., Tzartos S., Mamalaki A., Etschmann B., Müller-Hermelink H.K., Koscielniak E., Barth S.*, Marx A.* - A Human Recombinant Autoantibody-based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth in vitro and in a Murine Transplantation Model.  J. Biomed. Biotechnol. 2010: Article ID 187621 (2010)
  33. Kampmeier F., Niesen J., Koers A., Ribbert M., Brecht A., Fischer R., Kießling F., Barth S.*, Thepen T.* – Rapid optical imaging of EGF-receptor expression with a single chain antibody SNAP-tag fusion protein. European Journal of Nuclear Medicine and Molecular Imaging 37(19): 1926-1934 (2010)
  34. Ribbert T., Thepen T., Tur M.K., Fischer R., Huhn M., Barth S. – Recombinant, ETA’-based CD64 immunotoxins: Improved efficacy by increased valency, both in vitro as well as in vivo in a chronic cutaneous inflammation model in hC64-transgenic mice. Br. J. Dermatology 2: 279-286 (2010)
  35. Joerissen H., Bektas N., Dahl E., Hartmann A., ten Haaf A., Di Fiore S., Kiefer H., Thess A., Barth S.*, Klockenbring T.*  - Production and characterization of monoclonal antibodies against RAI3 and its expression in human breast cancer. BMC Cancer 9: 200 (2009)
  36. Kampmeier F., Ribbert M., Nachreiner T., Demsky S., Beaufils F., Brecht A., Barth S. – Site- specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-methylguanine DNA alkyltransferase. Bioconjug. Chem. 20(5): 1010-1015 (2009)
  37. Ranft K., Thepen T., Fischer R., Barth S.*, Stöcker M.* - Recombinant bispecific single chain antibody fragments induce Fc-gamma receptor mediated elimination of CD30+ lymphoma cells. Cancer Lett. 282(2): 187-194 (2009)
  38. Tur M.K., Neef I., Jäger G., Teubner A., Stöcker M., Melmer G., Barth S. – Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy.  Current  Pharmaceutical Design: Current Pharmaceutical Design 15 (23): 2693-2699 (2009)
  39. Tur M.K., Neef I., Jost E., Galm E., Jäger G., Stöcker M., Ribbert M., Osieka R., Barth S. – Targeted restoration of downregulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J. Immunother. 32 (5): 431-441 (2009)
  40. Stahnke B., Thepen T., Stöcker M., Rosinke R., Jost E., Fischer R., Tur M.K., Barth S. – Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukaemia of monocyte subtypes. Molecular Cancer Therapeutics 7(9): 2924-2932 (2008)
  41. Wüllner U., Neef I., Eller A., Kleines M., Tur M.K., Barth S. – Cell-Specific Induction of Apoptosis by Rationally Designed Bivalent Aptamer-siRNA Transcripts Silencing Eukaryotic Elongation Factor 2. Curr. Cancer Drug Targets 8(7): 554-465 (2008)
  42. Hetzel C., Bachran C., Fischer R., Fuchs H., Barth S.*, Stöcker M.* – Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin against CD64-positive acute myeloid leukemia cells. J. Immunother. 31(4): 370-376 (2008)
  43. Nachreiner T., Kampmeier F., Thepen T., Fischer R., Barth S.*, Stöcker M.* – Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. J. Neuroimmunology 195(1-2): 28-35 (2008)
  44. Stöcker M., Pardo A., Hetzel C., Reutelingsperger C., Fischer R., Barth S. – Eukaryotic expression and secretion of EGFP-labeled annexin A5. Prot. Expr. Purif. 58: 325-331 (2008)
  45. Bruell D., Bruns C.J., Yezhelyev M., Huhn M., Müller J., Ischenko I., von der Decken V., Fischer R., Finnern R., Jauch K.W., Barth S. – Recombinant anti-EGFR immunotoxin 425(scFv)-ETA’ demonstrates strong anti-tumor effect against disseminated human pancreatic cancer in nude mice. Int. J. Molec. Med. 15(2): 305-313 (2005)
  46. Paetz A., Sack M., Thepen T., Tur M.K., Bruell D., Finnern R., Fischer R., Barth S. – Recombinant soluble human Fcg receptor I with picomolar affinity for immunoglobulin G. Biochem. Biophys. Res. Commun. 338: 1811-1817 (2005)
  47. Stöcker M., Klockenbring T., Huhn M., Nachreiner T., Wicklein D., Petersen A., Bauer R., Goerlich R., Fischer R., Barth S. – Antigen-specific targeting and elimination of EBV- transformed B-cells by allergen-toxins. Journal of Allergy and Clinical Immunology 116(4): 910-915 (2005)
  48. Klimka A., Tur M.K., Huhn M., Bierfreund U., Terrada E., Fischer R., Finnern R., Barth S. – Measurement of antibody-membrane interactions by surface plasmon resonance. Int. J. Molec. Med. 14(4): 765-768 (2004)
  49. Rothe A., Klimka A., Tur M.K., Pfitzner T., Huhn M., Sasse S., Mallmann P., Engert A., Barth S. – Construction of phage display libraries from reactive lymph nodes of mammary carcinoma patients and selection of a breast cancer specific human single chain Fv. Int. J. Molec. Med. 14(4): 729-735 (2004)
  50. Bruell D., Stöcker M., Huhn M., Redding N., Küpper M., Schumacher P., Bruns C.J., Haisma H.J., Fischer R., Finnern R., Barth S. – The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA’ that suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int. J. Oncology 23 (4): 1179-1186 (2003)
  51. Tur M.K., Huhn M., Thepen T., Stöcker M., Krohn R., Vogel S., Jost E., Osieka R., van de Winkel J.G., Fischer R., Finnern F., Barth S. - Recombinant CD64-specific single chain Immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 63 (23): 8414-8419 (2003)
  52. Tur M.K., Rothe A., Huhn M., Goerres U., Klimka A., Stocker M., Engert A., Fischer R., Finnern R., Barth S. – A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. Int. J. Molec. Med. 11 (4): 523-527 (2003)
  53. Tur M.K., Huhn M., Sasse S., Engert A., Barth S. - Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages. BioTechniques 30 (2): 404-413 (2001)
  54. Tur M.K., Sasse S., Stöcker M., Djabelkhir K., Huhn M., Matthey B., Gottstein C., Engert A., Barth S. – An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int. J. Molec. Medicine 8(5): 579-584 (2001)
  55. Barth S., Huhn M., Matthey B., Klimka A., Galinski E.A., Engert A. - Compatible solute- supported periplasmic expression of functional recombinant proteins under stress conditions. Appl. Environm. Microbiol. 66(4): 1572-1579 (2000)
  56. Barth S., Huhn M., Matthey B., Tawadros S., Schnell R., Diehl V., Engert A. - Ki-4(scFv)-ETA’, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 95 (12): 3909-3914 (2000)
  57. Barth S., Huhn M., Matthey B., Schnell R., Tawadros S., Schinköthe T., Lorenzen J., Diehl V., Engert A. - Recombinant anti-CD25 immunotoxin RFT5(scFv)-ETA’ demonstrates successful elimination of disseminated human Hodgkin´s lymphoma in SCID mice. Int. J. Cancer 86: 718- 724 (2000)
  58. Barth S., Weidenmüller U., Tur M.K., Schmidt M.F.G., Engert A. - Combining phage display and screening of cDNA expression libraries: A new approach for identifying the target antigen of an scFv preselected by phage display. J. Mol. Biol. 301 (4): 751-757 (2000)
  59. Pfitzner T., Engert A., Wittor H., Schinköthe T., Winkler U., Schulz H., Diehl V., Barth S. - A real-time PCR assay for the quantification of residual malignant cells in monoclonal B-cell lymphomas. Leukemia 14: 754-766 (2000)
  60. Barth S., Matthey B., Huhn M., Diehl V., Engert A. - CD30L-ETA’: A new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma. Cytok. Cell. Molec. Ther. 5: 69-78 (1999)
  61. Matthey B., Klimka A., Diehl V., Engert A., Barth S. - A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene 229: 145- 153 (1999)
  62. Barth S., Huhn M., Wels W., Diehl V., Engert A. - Construction and in vitro evaluation of RFT5(scFv)-ETA’, a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int. J. Molec. Med. 1: 249-256 (1998)
  63. Barth S., Goerlich R., Schnabl H. - Selection and enrichment of differentially labeled plant protoplasts. J. Biochem. Biophys. Meth. 29: 83-86 (1994)
  64. Barth S., Voeste D., Schnabl H. - Somatic hybrids of sunflower (Helianthus annuus L.) identified at the callus stage by isoenzyme analysis. Bot. Acta 106: 100-102 (1993)
  65. Barth S., Voeste D., Wingender R., Schnabl H. - Plantlet regeneration from electrostimulated protoplasts of sunflower (Helianthus annuus L.). Bot. Acta 106: 220-222 (1993)

b)            Co-Author

  1. Maskus D.J., Bethke S., Seidel M., Kapelski S., Addai-Mensah O., Boes A., Edgü G., Spiegel H., Reimann A., Fischer R., Barth S., Klockenbring T., Fendel R. – Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. Malaria J 14(1): 276 (2015), PMID: 26174014., doi: 10.1186/s12936-015-0797-x.
  2. ten Haaf A., Pscherer S., Fries K., Barth S., Gattenlöhner S., Tur M.K. - On slide selection of patient SCLC tissue (FFPE) for generation of novel diagnostic and therapeutic antibodies by phage display. Immunol Let 166(2): 65-78 (2015), PMID: 26045318, doi: 10.1016/j.imlet.2015.05.013.
  3. Eersels K., van Grinsven B., Korshid M., Somers V., Püttmann C., Stein C., Barth S., Dilien H., Bos G., Germeraad W., Cleij T., Thoelen R., De Ceuninck W., Wagner P. - Heat-transfer method based cell culture quality assay through cell detection by surface imprinted polymers. Langmuir 31(6): 2043-2050 (2015), PMID: 25654744, doi: 10.1021/la5046173.
  4. Eersels K., van Grinsven B., Vandenryt T., Monroy K.L.J., Peeters M., Somers V., Püttmann C., Stein C., Barth S., Bos G., Germeraad W., Dilien H., Cleij T.J., Thoelen R., De Ceuninck W., Wagner P. - Improving the sensitivity of the heat-transfer method (HTM) for cancer cell detection with optimized sensor chips. Phys Status Solidi A 1(7): accepted (2015), doi: 10.1002/pssa.201431709.
  5. Kapelski S., Boes A., Spiegel H., de Almeida M., Klockenbring T., Reimann A., Fischer R., Barth S., Fendel R. - Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody. Malaria J 14(1):  50 (2015),  PMID: 25651860, doi: 10.1186/s12936-015-0577-7.
  6. Gremse F., Theek B., Kunjachan S., Lederle W., Pardo A., Barth S., Lammers T., Naumann U., Kiessling F. - Absorption reconstruction improves biodistribution assessment of fluorescent nanoprobes using hybrid fluorescence-mediated tomography. Theranostics 4(10): 960-971 (2014), PMID: 25157277, doi: 10.7150/thno.9293.
  7. Kapelski S., Klockenbring T., Fischer R., Barth S., Fendel R. - Assessment of the neutropilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum. J Leukocyte Biol 96(6): 1131-1142 (2014), PMID: 251118179, doi: 10.1189/jlb.4A0614-283RR.
  8. Bers K., Eersels K., van Grinsven B., Daemen M., Bogie J.F., Hendriks J.J., Bouwmans E.E., Püttmann C., Stein C., Barth S., Bos G.M., Germeraad W.T., De Ceuninck W., Wagner P. - Heat-transfer resistance measurement method (HTM)-based cell detection at trace levels using a progressive enrichment approach with highly selectice cell binding surface imprints. Langmuir 30(12): 3631-3639 (2014), PMID: 24606112, doi: 10.1021/la5001232.
  9. Höfig I., Barth S., Salomon M., Jagusch V., Atkinson M.J., Anastasov N., Thirion C. - Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein. Biomaterials 35(13): 4204-4212 (2014), PMID: 24529898, doi: 10.1016/j.biomaterials.2014.01.051.
  10. Buchenauer A., Bialon M., Segun D., Püttmann C., Stein C., Barth S., Schnakenberg U. - Plasmonic flow-through biosensor using a polymeric substrate. J Micromech Microeng 24(3): 034001 (2014)
  11. Amoury M., Blume T., Brehm H., Niesen J., Tenhaef N., Barth S., Helfrich W., Fitting J., Nachreiner T., Pardo A. – SNAP-Tag based agents for preclinical in vitro imaging in malignant diseases. Current Pharmaceutical Design 19: 5429-5436 (2013)
  12. Frese J., Schuster P., Mertens M.E., Vogg A., Dahlems U., Rongen L., Koch S., Mela P., Melmer G., Barth S., Mottaghy F.M., Schmitz-Rode T., Lammers T., Jockenhövel S., Kiessling F. - Generation and imaging of patient customized implants. Biomed. Tech. 09: 57 (2012)
  13. Fet N., Fiebeler A., Klinge U., Park J.K., Barth S., Thepen T., Tolba R. – Reduction of activated monocytes after ischemia reperfusion injury diminishes oxidative stress and ameliorates renal damage. Nephrol. Dial. Transplant. 27(8): 3149-3155 (2012)
  14. Hischemöller A., Walter C., Weiler V., Hummel H., Thepen T., Huhn M., Barth S., Hoheisel W., Köhler K., Bremer C., Haase M., Waldeck J. – Labeling of anti-MUC-1 binding single chain Fv fragments to surface upconversion nanoparticles for an initial in vivo molecular imaging proof of principle approach. Int J Mol Sci 13(4): 4153-4167 (2012)
  15. Dreier A., Barth S., Goswami A., Weis J. – Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? Tumour Biol. 33(1): 85-94 (2011)
  16. Abou-Elkacem L., Gremse F., Barth S., Hoffman R.F., Kiessling F., Lederle W. – Comparison of µCT, MRI, and optical reflectance imaging for assessing the growth of GFP/RFP-expressing tumors. Anticancer Res 31(9): 2907-2913 (2011)
  17. Kraus S., Kleines M., Albers J., Blohm L., Piechotta G., Püttmann C., Barth S., Nähring J., Nebling E. – Quantitative measurement of human anti-HCV core immunoglobulins on an electrical bioship platform. Biosensors Bioelectronics 26(5): 1895-1901 (2011)
  18. Recker T., Haamann D., Schmitt A., Küster A., Klee D., Barth S., Müller-Newen G. – Directed covalent immobilization of fluorescently labeled cytokines. Bioconjug. Chem. 22(6): 1210-1220 (2011)
  19. Simon-Keller K., Paschen A.,  Eichmüller  S., Gattenlöhner S., Barth S.,  Koscielniak E., Leuschner I., Stöber P., Hombach A., Abken H., Marx A. – Adoptive T-cell therapy of rhabdomyosarcoma. Pathologe 31 (S2): 215-220 (2010)
  20. Schmitt K., Bolwien C., Sulz G., Koch W., Dunkhorst W., Lödding H., Schwarz K., Holländer A., Klockenbring T., Barth S., Seidel B., Hofbauer W., Rennebarth T., Renzl A. – Fast detection of air contaminants using immunobiological methods. Proceedings of the SPIE – The International Society for Optical Engineering: 736207-736219 (2009)
  21. Thumann G., Stöcker M., Maltusch C., Salz A., Barth S., Walter P., Johnen S. – High efficient non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Therapy 17(2): 181-189 (2009)
  22. Rechmann H., Friedrich A., Forouzan D., Barth S., Schnabl H., Biselli M., Boehm R. – Characterization of photosynthetically active duckweed (Wolffia australiana) in vitro culture by respiration activity monitoring system (RAMOS). Biotechnol. Lett. 29(6): 971-977 (2007)
  23. Ribbert M., Wolters A., Barth S., Stoecker M., Fischer R., Finnern R. – Immunodetection of Venturia inaequalis ascospores with phage antibodies. J Phytopathology 155(3): 170-177 (2007)
  24. Wicklein D., Stöcker M., Klockenbring T., Huhn M., Wodrich M., Haas H., Becker W.M., Barth S., Petersen A. – In contrast to specific B cells, human basophils are unaffected by the toxic activity of an allergen toxin due to lack of internalization of immunoglobulin E-bound allergen. Clinical and Exp. Allergy 36: 531-542 (2006)
  25. Kupper M., Huhn M., Spiegel H., Ma J.K., Barth S., Fischer R., Finnern R. – Generation of human antibody fragments against Streptococcus mutans using a phage display chain shuffling approach. BMC Biotechnol. 5(1): 4 (2005)
  26. Heuser C., Barth S., Diehl V., Abken H., Hombach A. – An anti-CD30-scFv-IL-2 antibody- cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin’s lymphoma-derived tumor cells. Int. J. Cancer 110(3): 386-394 (2004)
  27. 92.          Matthey B., Borchmann P., Schnell R., Tawadros S., Lange H., Tur M.K., Huhn M., Klimka A., Barth S., Engert A., Hansen H.P. – Metalloproteinase inhibition augments anti-tumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA’ against human lymphomas in vivo. Int. J. Cancer 111(4): 568-574 (2004)
  28.   Stöcker M., Tur M.K., Sasse S., Krüßmann A., Barth S., Engert A. – Secretion of functional anti-CD30 angiogenin immunotoxins into the supernatant of transfected 293T cells. Prot. Expr. Purif 28 (2): 211-219 (2003)
  29. Adili F., Scholz T., Hille M., Heckenkamp J., Barth S., Engert A., Schmitz-Rixen T., Photodynamic therapy mediated iduction of accelerated re-endothelialisation following injury to the arterial wall: Implications for the prevention of postinterventional restenosis. EJVES 24: 166-175 (2002)
  30. Hansen H.P., Matthey B., Barth S., Kisseleva T., Mokros T., Davies S.J., Beckett R.P., Foelster-Holst R., Lange H.H., Engert A., Lemke H. - Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int. J. Cancer 98(2): 210-215 (2002)
  31. Kruse C., Boehm R., Voeste D., Barth S., Schnabl H. - Transformation of duckweed (Wolffia columbiana) by particle bombardment. Aquatic Botany, Vol. 72 (2): 175-181 (2002)
  32. Pfister K., Wittig B.M., Jüngling B., Ecker K.W., Barth S., Huhn M., Sasse S., Engert A., Mueller-Molaian I., Diehl V., Zeitz M., Stallmach A. – The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice. Int. J. Colorectal Disease 17: 77-84 (2002)
  33. Pfitzner T., Reiser M., Barth S., Borchmann P., Schulz H., Schinköthe T., Oberhäuser F., Wessels J., Tur M.K., Diehl V., Engert A. – Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 81(5): 258-266 (2002)
  34. Boehm R., Kruse C., Voeste D., Barth S., Schnabl H. - A transient transformation system for duckweed (Wolffia columbiana) using Agrobacterium-mediated gene transfer. J. Appl. Bot. 75: 107-111 (2001)
  35. Huhn M., Sasse S., Tur M.K., Matthey B., Schinköthe T., Rybak S., Barth S., Engert A. - Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 61(24): 8737-8742 (2001)
  36. Sundarapandiyan K., Keler T., Behnke D., Engert A., Barth S., Matthey B., Deo Y.M., Graziano R.F. - Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. J. Immunol. Meth. 248 (1-2): 113-123 (2001)
  37. Klimka A., Matthey B., Roovers R., Barth S., Bot F., Arends J.W., Engert A., Hoogenboom H.R. - Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. Brit. J. Cancer 83: 252-260 (2000)
  38. Schnell R., Vitetta E., Schindler J., Borchmann P., Barth S., Ghetie V., Hell K., Drillich S., Diehl V., Engert A. - Treatment of refractory Hodgkin´s lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leuk. 14: 129-135 (2000)
  39. Klimka A., Barth S., Matthey B., Roovers R.C., Lemke H., Hansen H., Arends J.W., Diehl V., Hoogenboom H.R., Engert A. - An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Brit. J. Cancer 80(8): 1214-1222 (1999)
  40. Schnell R., Vitetta E.S., Schindler J., Barth S., Winkler U., Borchmann P., Hansmann M.L., Diehl V., Ghetie V., Engert A. - Experimental and clinical trials with an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in Hodgkin´s lymphoma. Leuk. Lymph. 30 (5-6): 525-537 (1998)
  41. Engert A., Diehl V., Schnell R., Radzuhn A., Hatwig M.T., Drillich S., Schön G., Bohlen H., Tesch H., Hansmann M.L., Barth S., Schindler J., Ghetie V., Uhr J., Vitetta E.S. - A phase-I  study of an anti-CD25 ricin A chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin´s lymphoma. Blood 89: 403-410 (1997)
  42. Klimka A., Barth S., Drillich S., Wels W., van Snick J., Renauld J.-C., Tesch H., Bohlen H., Diehl V., Engert A. - A deletion mutant of Pseudomonas exotoxin-A fused to human interleukin- 9  (rhIL9-ETA')  shows  specific  cytotoxicity  against  IL-9-receptor  expressing  cell  lines. Cytokines Mol. Ther. 2: 139-146 (1996)
  43. Schnell R., Katouzi A.A., Linnartz C., Schoen G., Drillich S., Hansmann M.L., Schiefer D., Barth S., Zangemeister-Wittke U., Stahel R.A., Diehl V., Engert A. - Potent antitumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt´s lymphoma model in SCID mice. Int. J. Cancer 66: 526-531 (1996)
  44. Wingender R., Henn H.J., Barth S., Voeste D., Machlab H., Schnabl H. - A regeneration protocol for sunflower (Helianthus annuus L.) protoplasts. Plant Cell Rep. 15: 742-745 (1996)
  45. Hoffmann E., Schönherr K., Johann P., Hampp R., von Keller A., Voeste D., Barth S., Schnabl H., Baumann T., Eisenbeiss M., Reinhard E. - Electrofusion of plant cell protoplasts under microgravity - A D-2 spacelab experiment. Microgravity Sci. Technol. 8(3): 188-195 (1995)
  46. Wingender R., Barth S., Dresen B., von Keller A., Kirches E., Machlab H., Schemionek A., Voeste D., Schnabl H. - Fusion of sunflower protoplasts: isoenzyme analysis and regeneration capacity. Biotechnol. Biotechnol. Equ. 7: 121-125 (1993)
  47. de Kathen A., Barth S., Jacobsen H.-J. - Entwicklung eines Agrobacterium tumefaciens- vermittelten Transformationssystems für Pisum sativum mit dem Ziel der Übertragung von Virus-Resistenzen (PSbMV). Schriftenreihe des BML Reihe A: 302-311 (1991)

Reviews

a)            First/Senior Author

  1. Berges N., Hehmann-Titt G., Hristodorov D., Melmer G., Thepen T., Barth S. - Human cytolytic fusion proteins: modified versions of human Granzyme B and Angiogenin have the potential to replace bacterial toxins in targeted therapies against CD64+ diseases. Antibodies 3(1): 92- 115 (2014)
  2. Schirrmann T., Steinwand M., Wezler X., Ten Haaf A., Tur M.K., Barth S. - CD30 as a therapeutic target for lymphoma. BioDrugs 28(2): 181-209 (2014), PMID: 24043362, doi: 10.1007/s40259-013-0068-8.
  3. Barth S. – The SNAP-tag technology – a versatile tool with many applications. Current Pharmaceutical Design 19: 5404-5405 (2013)
  4. Hussain A.F., Amoury M., Barth S. – SNAP-Tag technology: a powerfull tool for site-specific conjugation of therapeutic agents. Current Pharmaceutical Design 19: 5437-5442 (2013)
  5. Kolberg K., Püttmann C., Pardo A., Fitting J., Barth S. – SNAP-Tag technology: a general introduction. Current Pharmaceutical Design 19: 5406-5413 (2013)
  6. Hehmann-Titt G., Schiffer S., Berges N., Melmer G, Barth S. – Improving the therapeutic potential of human granzyme B for targeted cancer therapy. Antibodies 2(1): 19-49 (2013)
  7. Rosenblum M.G., Barth S. – Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Current Pharmaceutical Design 15 (23): 2676-2692 (2009)
  8. Thepen T., Huhn M., Melmer G., Tur M.K., Barth S. – Fcg receptor 1 (CD64), a target beyond cancer therapy. Current Pharmaceutical Design 15 (23): 2712-2718 (2009)
  9. Barth S. – Recombinant immunotoxins – The next generation. Current Pharmaceutical Design 15 (23): 2650-2651 (2009)
  10. Wüllner U., Neef I., Tur M.K., Barth S. – Targeted delivery of RNA interference based drugs. Strategies for in vivo delivery of RNA interference based drugs. Recent Patents in anti-Cancer Drug Discovery 4(1): 1-8 (2009)
  11. Barth S. – The next generation of recombinant immunotoxins. Pharma Focus Asia 5: 29-31 (2007)
  12. Wei M.Q., Metharom P., Ellem K.A., Barth S. – Search for „weapons of mass destruction“ for cancer – immuno/gene therapy comes of age. Cell. Mol. Immunol. 2(5): 351-357 (2005)
  13. Thepen T., Huhn M., Barth S. – Auflösung chronischer Entzündungen durch Bändigung abtrünniger Makrophagen: Eliminierung von Hyde aus “Jekyll und Hyde“-Makrophagen. BIOforum 11: 42-22 (2004)
  14. Barth S. – BL22. Current Opinion in Molecular Therapeutics 4: 72-75 (2002)
  15. Barth S. - hIL13-PE38PQQR. Current Opinion in Investigational Drugs 2: 1309-1313 (2001)
  16. Matthey B., Engert A., Barth S. – Recombinant immunotoxins for the treatment of Hodgkin´s disease. Int. J. Molec. Med. 6(5): 509-514 (2000)
  17. Barth S., Winkler U., Diehl V., Engert A. - Immuntoxine. Wirkungsweise und Einsatz bei malignen Erkrankungen. Der Internist 38: 1063-1069 (1997)
  18. Barth S., Schnell R., Diehl V., Engert A. - Development of immunotoxins for potential clinical use in Hodgkin´s disease. Annals Oncol. 7 (Suppl. 4): 135-141 (1996)

b)            Co-Author

  1. Simon-Keller K., Barth S., Vincent A., Marx A. – Targeting the fetal acetylcholine receptor in rhabdomyosarcoma. Expert Opin Ther Targets 17(2): 127-138 (2013)
  2. Hristodorov D., Mladenov R., Huhn M., Barth S., Thepen T. – Macrophage-targeted therapy: C64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins 4(9): 676- 694 (2012)
  3. Simon-Keller K., Paschen A.,  Eichmüller  S., Gattenlöhner S., Barth S.,  Koscielniak E., Leuschner I., Stöber P., Hombach A., Abken H., Marx A. – Adoptive T-cell therapy of rhabdomyosarcoma. Pathologe 31: 215-220 (2010)
  4. Pfitzner T., Barth S., Engert A. - Tumorvakzine: Immuntherapie im Jahr 2000. Der Onkologe: Suppl. 1: S31-S35 (2000)
  5. Engert A., Schnell R., Barth S., Diehl V. - Immuntherapeutische Strategien bei Lymphomen. Der Internist 38: 150-156 (1997)
  6. Schnell R., Barth S., Diehl V., Engert A. - Non-Hodgkin´s lymphoma: A review of immunotherapeutic approaches to treatment. BioDrugs 8: 216-234 (1997)
  7.   Winkler U., Barth S., Schnell R., Diehl V., Engert A. - The emerging role of immunotoxins in leukemia and lymphoma. Annals Oncol. 8 (Suppl. 1): 139-146 (1997)
  8. Schnell R., Barth S., Diehl V., Engert A. - Hodgkin’s disease. Future treatment strategies: fact of fiction? Baillieres Clin Haematol 9(3): 573-593 (1996)
  9. Schnell R., Barth S., Diehl V., Engert A. - Bieten Immuntoxine eine neue Perspektive in der internistischen Onkologie? Forum DKG 10: 278-284 (1995)
  10. Schnell R., Barth S., Diehl V., Engert A. - Immuntoxine - Eine Alternative in der onkologischen Therapie ? Therapiewoche 27: 1608-1614 (1995)

Book Chapters

a)            First-/Senior Author

  1. Cremer C., Hehmann-Titt G., Schiffer S., Melmer G., Carloni P., Barth S.*, Nachreiner T.* - Engineered versions of granzyme B and angiogenin overcome intrinsic resistance to apoptosis mediated by human cytolytic fusion proteins. In Verma R.S., Resistance to immunotoxins in cancer therapy. Springer, ISSN 2196-5501 (2015)
  2. Hussain A.F., Wüllner U., Neef I., Tur M.K., Barth S. – Targeted delivery of short interfering RNAs for in vivo applications. In: Atta-ur-Rahman, Zaman K., Topics in Anti-Cancer Research, Bentham Science Publishers, ISSN 2213-3585: 228-253 (2012)
  3. Fuchs H., Barth S. - Immunotoxins. In M. Schwab (Ed.) Encyclopedia of Cancer, Springer (2009)
  4. Fuchs H., Barth S. - Ribosome-inactivating proteins. In M. Schwab (Ed.) Encyclopedia of Cancer, Springer (2009)
  5. Tur M.K., Barth S. – Immunotherapy. In M. Schwab (Ed.) Encyclopedia of Cancer, Springer (2009)
  6. Weidenmüller U., Tur M.K., Engert A., Barth S. - Detection of disease-related surface antigens by combining phage display and cDNA expression library screening. In: M.P. Weiner, Q. Lu (eds.) GENE CLONING & EXPRESSION TECHNOLOGIES, BioTechniques® Books/Eaton Publishing: 521-525 (2002)
  7. Pfitzner T., Engert A., Barth S. - Quantification of residual tumor cells in monoclonal B-cell lymphoma. Springer (2001)

b)            Co-Author

  1. Hristodorov D., Mladenov R., Aslanian M., Huhn M., Barth S., Thepen T. - Chapter 12: Macropage-targeted thrapy of chronic wounds. In: Chang W.C., Chang W.C., Chronic Inflammation: causes, treatment options and role in disease, Nova Publishers, ISBN-10: 1628080949
  2. Schnell R., Barth S., Engert A. - Der therapeutische Einsatz von monoklonalen Antikörpern und Immuntoxinen beim Morbus Hodgkin. Kneba (2000)
  3. Schnell R., Barth S., Diehl V., Engert A. - Future treatment strategies: Fact or fiction? In V. Diehl (ed.) Baillière's Clinical Haematology: Hodgkin´s disease. WB Saunders Company Ltd, London: 573-594 (1996)

Books

  1. Barth S. – Next generation of recombinant immunotoxins. Special issue editored in Current Pharmaceutical Design, ISSN 1381-6128, Volume 15, Number 23, (2009)

 

Stefan Barth

South African Research Chair in Cancer Biotechnology

  • Institute of Infectious Disease and Molecular Medicine
    University of Cape Town
  • COUNTRY South Africa